Cargando…
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
OBJECTIVE: Patients with melanoma and early stable disease (SD) with pembrolizumab have unclear prognosis. We present post hoc analyses of long-term outcomes for patients with early SD, partial response (PR) or complete response (CR) with pembrolizumab. PATIENTS AND METHODS: Patients who received pe...
Autores principales: | Hamid, Omid, Robert, Caroline, Daud, Adil, Carlino, Matteo S., Mitchell, Tara C., Hersey, Peter, Schachter, Jacob, Long, Georgina V., Hodi, F. Stephen, Wolchok, Jedd D., Arance, Ana, Jacques Grob, Jean, Joshua, Anthony M., Weber, Jeffrey S., Mortier, Laurent, Jensen, Erin, Diede, Scott J., Homet Moreno, Blanca, Ribas, Antoni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350885/ https://www.ncbi.nlm.nih.gov/pubmed/34571336 http://dx.doi.org/10.1016/j.ejca.2021.08.013 |
Ejemplares similares
-
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
por: Hamid, Omid, et al.
Publicado: (2018) -
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
por: Hamid, O, et al.
Publicado: (2019) -
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
por: Gangadhar, Tara C., et al.
Publicado: (2017) -
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
por: Bratland, Åse, et al.
Publicado: (2023) -
Keynotes
Publicado: (2023)